Imatinib mesylate causes genome-wide transcriptional changes in systemic sclerosis fibroblasts in vitro

Clinical and Experimental Rheumatology

Volumn 30, Issue SUPPL.71, 2012, Pages

  Hinchcliff, Monique ^a   Huang, Chiang Ching ^a   Ishida, Wataru ^a   Fang, Feng ^a   Lee, Jungwha ^a   Jafari, Nadereh ^a   Wilkes, Mark ^b   Bhattacharyya, Swati ^a   Leof, Edward ^b   Varga, John ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b MAYO GRADUATE SCHOOL   (United States)

Author keywords

DNA microarray; Imatinib mesylate; Proto oncogene proteins c Abl; Systemic scleroderma

Indexed keywords

ABELSON KINASE; IMATINIB; TRANSFORMING GROWTH FACTOR BETA; PIPERAZINE DERIVATIVE; PROTEIN KINASE INHIBITOR; PYRIMIDINE DERIVATIVE; TRANSFORMING GROWTH FACTOR BETA1;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CHOLESTEROL METABOLISM; CLINICAL ARTICLE; CONTROLLED STUDY; DNA MICROARRAY; DRUG MECHANISM; EMBRYO; ENZYME ACTIVATION; FEMALE; GENE EXPRESSION REGULATION; GENE EXPRESSION SYSTEM; GENETIC ASSOCIATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; LIPID METABOLISM; MALE; MICROARRAY ANALYSIS; MOUSE; NONHUMAN; PHARMACOLOGICAL BLOCKING; PRIORITY JOURNAL; SKIN BIOPSY; SKIN FIBROBLAST; SYSTEMIC SCLEROSIS; TISSUE LEVEL; TRANSCRIPTION REGULATION; ANIMAL; BIOPSY; CASE CONTROL STUDY; CELL CULTURE; DRUG ANTAGONISM; DRUG EFFECT; ENZYMOLOGY; FIBROBLAST; FIBROSIS; GENE EXPRESSION PROFILING; GENETIC TRANSCRIPTION; GENETICS; METABOLISM; METHODOLOGY; MOUSE MUTANT; PATHOLOGY; PHOSPHORYLATION; SIGNAL TRANSDUCTION; SKIN; TIME;

ANIMALS; BIOPSY; CASE-CONTROL STUDIES; CELLS, CULTURED; FIBROBLASTS; FIBROSIS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HUMANS; MICE; MICE, KNOCKOUT; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PHOSPHORYLATION; PIPERAZINES; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-ABL; PYRIMIDINES; SCLERODERMA, SYSTEMIC; SIGNAL TRANSDUCTION; SKIN; TIME FACTORS; TRANSCRIPTION, GENETIC; TRANSFORMING GROWTH FACTOR BETA1;

EID: 84867379154     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (52)

1. Hinchcliff M, Varga J: Systemic sclerosis/ scleroderma: a treatable multisystem disease. Am Fam Physician 2008; 78: 961-8.
2. Varga J, Pasche B: Transforming growth factor beta as a therapeutic target in systemic sclerosis. Nat Rev Rheumatol 2009; 5: 200-6.
3. Trojanowska M: Noncanonical transforming growth factor beta signaling in scleroderma fibrosis. Curr Opin Rheumatol 2009; 21: 623-9.
4. Goldman JM, Melo JV: Targeting the BCRABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001; 344: 1084-6.
5. Daniels CE et al.: Imatinib mesylate inhibits the profibrogenic activity of TGF-beta and prevents bleomycin-mediated lung fibrosis. J Clin Invest 2004; 114: 1308-16.
6. Bhattacharyya S, Ishida W, WU M et al.: A non-Smad mechanism of fibroblast activation by transforming growth factor-beta via c- Abl and Egr-1: selective modulation by imatinib mesylate. Oncogene 2009; 28: 1285-97.
7. Distler JH, Distler O: Imatinib as a novel therapeutic approach for fibrotic disorders. Rheumatology (Oxford) 2009; 48: 2-4.
8. Distler JH, Jüngel A, Huber LC et al.: Imatinib mesylate reduces production of extracellular matrix and prevents development of experimental dermal fibrosis. Arthritis Rheum 2007; 56: 311-22.
9. Takimoto C, Calvo E: Principles of Oncologic Pharmacotherapy" in R. PAZDUR et al., (Eds.) Cancer Management: A Multidisciplinary Approach, 11th ed. 2008.
10. Druker BJ, Talpaz M, Resta DJ et al.: Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001; 344: 1031-7.
11. Joensuu H, Roberts PJ, Sarlomo-Rikala M et al.: Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med 2001; 344: 1052-6.
12. Wang S, Wilkes MC, Leof EB, Hirschberg R.: Imatinib mesylate blocks a non-Smad TGF-beta pathway and reduced renal fibrogenesis in vivo. FASEB J 2005; 19: 1-11.
13. Wilkes MC, Leof EB: Transforming growth factor beta activation of c-Abl is independent of receptor internalization and regulated by phosphatidylinositol 3-kinase and PAK2 in mesenchymal cultures. J Biol Chem 2006; 281: 27846-54.
14. Gordon J: Personal communication, M. Hinchcliff, Editor 2011.
15. Daniels CE, Lasky JA, Limper AH, Mieras K, Gabor E, Schroeder DR: Imatinib treatment for idiopathic pulmonary fibrosis: Randomized placebo-controlled trial results. Am J Respir Crit Care Med 2010; 181: 604-10.
16. Sabnani I, Zucker MJ, Rosenstein ED et al.: A novel therapeutic approach to the treatment of scleroderma-associated pulmonary complications: safety and efficacy of combination therapy with imatinib and cyclophosphamide. Rheumatology (Oxford) 2009; 48: 49-52.
17. Spiera RF, Gordon JK, Mersten JN, et al.: Imatinib mesylate (Gleevec) in the treatment of diffuse cutaneous systemic sclerosis: results of a 1-year, phase IIa, single-arm, openlabel clinical trial. Ann Rheum Dis 2011; 70: 1003-9.
18. Tamaki Z, Asano Y, Hatano M et al.: Efficacy of low-dose imatinib mesylate for cutaneous involvement in systemic sclerosis: a preliminary report of three cases. Mod Rheumatol 2011; 22: 94.9.
19. Pope J et al.: A Proof of Concept Trial of Gleevec (Imatinib) in Active Diffuse Scleroderma (DSSc), in American College of Rheumatology Annual Scientific Meeting 2009, Arthritis and Rheumatism: Philadelphia, PA. p. S227.
20. Gardner H, Shearstone JR, Bandaru R et al.: Gene profiling of scleroderma skin reveals robust signatures of disease that are imperfectly reflected in the transcript profiles of explanted fibroblasts. Arthritis Rheum 2006; 54: 1961-73.
21. Whitfield ML, Finlay DR, Murray JI et al.: Systemic and cell type-specific gene expression patterns in scleroderma skin. Proc Natl Acad Sci USA 2003; 100: 12319-24.
22. Sargent JL, Milano A, Bhattacharyya S et al.: A TGFbeta-responsive gene signature is associated with a subset of diffuse scleroderma with increased disease severity. J Invest Dermatol 2010; 130: 694-705.
23. Chung L, Fiorentino DF, Benbarak MJ et al.: Molecular framework for response to imatinib mesylate in systemic sclerosis. Arthritis Rheum 2009; 60: 584-91.
24. Mori Y, Ishida W, Bhattacharyya S et al.: Selective inhibition of activin receptorlike kinase 5 signaling blocks profibrotic transforming growth factor beta responses in skin fibroblasts. Arthritis Rheum 2004; 50: 4008-21.
25. Mori Y, Chen SJ, Varga J: Modulation of endogenous Smad expression in normal skin fibroblasts by transforming growth factorbeta. Exp Cell Res 2000; 258: 374-83.
26. Ksienski D: Imatinib mesylate: past successes and future challenges in the treatment of gastrointestinal stromal tumors. Clin Med Insights Oncol 2011; 5: 365-79.
27. Jing Y, Song Z, Wang M, Tang W, Hao S, Zeng X: c-Abl tyrosine kinase regulates c-fos gene expression via phosphorylating RNA polymerase II. Arch Biochem Biophys 2005; 437: 199-204.
28. Mori Y, Chen SJ, Varga J: Expression and regulation of intracellular SMAD signaling in scleroderma skin fibroblasts. Arthritis Rheum 2003; 48: 1964-78.
29. Du P, Kibbe WA, Lin SM: nuID: a universal naming scheme of oligonucleotides for illumina, affymetrix, and other microarrays. Biol Direct 2007; 2: 16.
30. Du P, Kibbe WA, Lin SM: Lumi: a pipeline for processing Illumina microarray. Bioinformatics 2008; 24: 1547-8.
31. Lin SM, Du P, Huber W, Kibbe WA: Modelbased variance-stabilizing transformation for Illumina microarray data. Nucleic Acids Res 2008; 36: e11.
32. Einhauer A, Jungbauer A: The FLAG peptide, a versatile fusion tag for the purification of recombinant proteins. J Biochem Biophys Methods 2001; 49: 455-65.
33. Chen SJ, Yuan W, Mori Y, Levenson A, Trojanowska M, Varga J: Stimulation of type I collagen transcription in human skin fibroblasts by TGF-beta: involvement of Smad 3. J Invest Dermatol 1999; 112: 49-57.
34. Varga J, Abraham D: Systemic sclerosis: a prototypic multisystem fibrotic disorder. J Clin Invest 2007; 117: 557-67.
35. Leung WK, Ching AK, Wong N: Phosphorylation of Caldesmon by PFTAIRE1 kinase promotes actin binding and formation of stress fibers. Molecular and Cellular Biochemistry 2011; 350: 201-6.
36. Pendyala S, Moitra J, Kalari S et al.: Nrf2 regulates hyperoxia-induced Nox4 expression in human lung endothelium: identification of functional antioxidant response element on the Nox4 promoter. Free Radic Biol Med 2011; 50: 1749-59.
37. Crestani B, Besnard V, Boczkowski J: Signalling pathways from NADPH oxidase-4 to idiopathic pulmonary fibrosis. Int J Biochem Cell Biol 2011; 43: 1086-9.
38. Craige SM, Chen K, Pei Y et al.: NADPH oxidase 4 promotes endothelial angiogenesis through endothelial nitric oxide synthase activation. Circulation 2011; 124: 731-40.
39. Carnesecchi S, Deffert C, Donati Y et al.: A key role for NOX4 in epithelial cell death during development of lung fibrosis. Antioxid Redox Signal 2011; 15: 607-19.
40. De Andrade JA, Thannickal VJ: Innovative approaches to the therapy of fibrosis. Curr Opin Rheumatol 2009; 21: 649-55.
41. Sbarouni E, Georgiadou P, Sklavainas I et al.: Increases in serum concentration of human heart-type fatty acid-binding protein following elective coronary intervention. Biomarkers 2009; 14: 317-20.
42. Muehlschlegel JD, Perry TE, Liu KY et al.: Heart-type fatty acid binding protein is an independent predictor of death and ventricular dysfunction after coronary artery bypass graft surgery. Anesth Analg 2010; 111: 1101-9.
43. Liao J, Chan CP, Cheung YC et al.: Human heart-type fatty acid-binding protein for onsite diagnosis of early acute myocardial infarction. Int J Cardiol 2009; 133: 420-3.
44. Giannessi D, Piacenti M, Maltinti M et al.: Heart-type fatty acid binding protein is an early marker of myocardial damage after radiofrequency catheter ablation. Clin Biochem 2010; 43: 1241-5.
45. Yao-Borengasser A, Rassouli N, Varma V et al.: Stearoyl-coenzyme A desaturase 1 gene expression increases after pioglitazone treatment and is associated with peroxisomal proliferator-activated receptor-gamma responsiveness. J Clin Endocrinol Metab 2008; 93: 4431-9.
46. Ecker J, Liebisch G, Grandl M, Schmitz G: Lower SCD expression in dendritic cells compared to macrophages leads to membrane lipids with less mono-unsaturated fatty acids. Immunobiology 2010; 215: 748-55.
47. Roussel L, Robins S, Schachter A, Bérubé J, Hamid Q, Rousseau S: Steroids and extracellular signal-regulated kinase 1/2 activity suppress activating transcription factor 3 expression in patients with severe asthma. J Allergy Clin Immunol 2011; 127: 1632-4.
48. Zhang T, Jia N, Fei E et al.: Nurr1 is phosphorylated by ERK2 in vitro and its phosphorylation upregulates tyrosine hydroxylase expression in SH-SY5Y cells. Neurosci Lett 2007; 423: 118-22.
49. Fury W, Batliwalla F, Gregersen PK, Li W: Overlapping probabilities of top ranking gene lists, hypergeometric distribution, and stringency of gene selection criterion. Conf Proc IEEE Eng Med Biol Soc 2006; 1: 5531-4.
50. Wei J, Ghosh AK, Sargent JL et al.: PPARgamma downregulation by TGFss in fibroblast and impaired expression and function in systemic sclerosis: a novel mechanism for progressive fibrogenesis. PLoS One 2010; 5: e13778.
51. Arakawa H, Jinnin M, Muchemwa FC et al.: Adiponectin expression is decreased in the involved skin and sera of diffuse cutaneous scleroderma patients. Exp Dermatol 2011; 20: 764-6.
52. Katsoulidis E, Sassano A, Majchrzakkita B et al.: Suppression of interferon (IFN)- inducible genes and IFN-mediated functional responses in BCR-ABL-expressing cells. J Biol Chem 2008; 283: 10793-803